Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Association of CD31 and p53 With Survival of Ovarian Cancer Patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND/AIM: New markers for ovarian cancer are needed. This study aimed to examine the expression of tumour cell p53 and endothelial cell CD31 proteins and correlate them to clinicopathological factors.

PATIENTS AND METHODS: Expression of proteins was immunohistochemically assessed using tissue sections from 585-599 ovarian cancer patients from the Danish MALOVA study.

RESULTS: High CD31 expression was found in poorly differentiated tumours (p=0.0006), and high p53 expression was found in poorly differentiated cancers (p<0.0001), high clinical stage (p<0.0001), non-radical surgery (p<0.0001) and high serum CA-125 values (p<0.0001). CD31 expression showed no prognostic survival value, but high hazard ratios were found for patients with high p53 expression (HR=2.313, p<0.0001). An interaction was found between p53 and stage of cancer, suggesting a prognostic impact of p53 in low-stage, but not in advanced-stage cancer.

CONCLUSION: More than 5% of p53 tissue expression may predict shorter survival of ovarian cancer patients and may be useful for predicting the risk of disease progression in low-stage patients following primary surgery. CD31 has no strong prognostic value.

Original languageEnglish
JournalAnticancer Research
Volume39
Issue number2
Pages (from-to)567-576
Number of pages10
ISSN0250-7005
DOIs
Publication statusPublished - Feb 2019

    Research areas

  • Biomarkers, Tumor/metabolism, Carcinoma, Ovarian Epithelial/metabolism, Cell Differentiation, Denmark, Disease Progression, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Neoplasm Staging, Ovarian Neoplasms/metabolism, Platelet Endothelial Cell Adhesion Molecule-1/metabolism, Prognosis, Risk Factors, Tumor Suppressor Protein p53/metabolism

ID: 58605882